HNFO With or Without Helmet NIV for Oxygenation Support in Acute Respiratory Failure Pilot RCT
Condition(s) studied
Investigational drug(s) / intervention(s)
Helmet Non-Invasive Ventilation (HNIV): HNIV will be connected to a ventilator by a conventional closed respiratory circuit. Sessions of HNIV will be delivered with PEEP targeting a minimum 12 hours/day. PEEP will be titrated according to patient comfort, work of breathing, and O2 saturation. Pressure support will be titrated to lowest level tolerated. Between HNIV sessions, patients will be supported with HFNO at the same required FiO2. Starting on study day 3, patients will be screened for discontinuation of HNIV. Once HNIV is stopped, patients will be transitioned to HFNO and then weaned from HFNO as tolerated.
High Flow Nasal Oxygen: HFNO will be provided. FiO2 will be titrated to achieve a target O2 saturation of 92-97%, and flows will be initiated at 50 litres/minute and titrated as per usual practice for comfort and oxygenation. Once the target O2 saturation is achieved, the FiO2 will be titrated to the minimal value to maintain this target saturation. HFNO will be provided continuously over a minimum of 2 calendar days. Starting on study day 3, patients will be weaned from HFNO as tolerated.
Study summary
This Randomized Control Trial will directly compare helmet non-invasive ventilation (NIV) combined with high flow nasal oxygen (HFNO) versus HFNO alone in patients with Acute Hypoxemic Respiratory Failure (AHRF).
Eligibility
Primary outcome measure(s)
- Recruitment Rates — 2 years
Recruitment rate at different study sites - Non-randomized Eligible Patients — 2 years
Proportion of Eligible patients who are not randomized and reasons for this - Adherence/Compliance to Oxygenation Strategy — 2 years
Rate of adherence to the assigned oxygenation strategy (and crossover rates) - Among patients requiring intubation in each group, the number who were intubated according to the pre-specified criteria — 2 years
Adherence to pre-specified criteria for intubation in each group - Time from ICU admission to randomization and initiation of treatment — 2 years
Median time from ICU admission to randomization and initiation of the allocated treatment
Trial sites (11)
| Facility | City | Region | Status |
|---|---|---|---|
| University of Calgary | Calgary | Alberta | |
| University of Alberta Hospital | Edmonton | Alberta | |
| Hamilton Health Sciences- Juravinski | Hamilton | Ontario | |
| Kingston General Hospital | Kingston | Ontario | |
| London Health Sciences Centre | London | Ontario | |
| Ottawa Hospital | Ottawa | Ontario | |
| North York General Hospital | Toronto | Ontario | |
| Sunnybrook Health Sciences Centre | Toronto | Ontario | |
| St. Michael's Hospital | Toronto | Ontario | |
| Mount Sinai Hospital | Toronto | Ontario | |
| University Health Network Toronto General | Toronto | Ontario |
More Sunnybrook Health Sciences Centre trials in Canada
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05078034 on ClinicalTrials.gov ↗ ← All trials in Canada